{"id":33792,"date":"2025-05-21T08:44:47","date_gmt":"2025-05-21T00:44:47","guid":{"rendered":"https:\/\/flcube.com\/?p=33792"},"modified":"2025-05-21T08:44:48","modified_gmt":"2025-05-21T00:44:48","slug":"regeneron-wins-auction-for-23andmes-core-business-units","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33792","title":{"rendered":"Regeneron Wins Auction for 23andMe&#8217;s Core Business Units"},"content":{"rendered":"\n<p>US-based biopharma Regeneron Pharmaceuticals Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe&#8217;s Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe&#8217;s Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe&#8217;s direct-to-consumer services post-acquisition.<\/p>\n\n\n\n<p><strong>Lemonaid Health Background<\/strong><br>Lemonaid Health, a virtual platform for online on-demand access to medical and pharmacy services, merged with 23andMe in a USD 400 million deal in October 2021. This added telemedicine and prescription drug delivery services to 23andMe&#8217;s consumer business. 23andMe reportedly considered selling the unit in January of this year.<\/p>\n\n\n\n<p><strong>23andMe Financial Overview<\/strong><br>Founded in 2006, 23andMe made its debut in 2021, reaching a peak market value of USD 6 billion. However, the company has never been profitable since its inception. As of December 31, 2024, its cash and cash equivalents totaled only USD 79.4 million. In March 2025, 23andMe filed for bankruptcy protection after unsuccessful attempts at privatization and acquisition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Regeneron-Enters-into-Asset-Purchase-Agreement-to-Acquire-23andMe\u00ae-for-256-Million-Plans-to-Maintain-Consumer-Genetics-Business-and-Advance-Shared-Goals-of-Improving-Human-Health-and-Wellness.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe\u00ae for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness.\"><\/object><a id=\"wp-block-file--media-c297dfb5-f743-4a6f-93fe-4f56b11f3507\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Regeneron-Enters-into-Asset-Purchase-Agreement-to-Acquire-23andMe\u00ae-for-256-Million-Plans-to-Maintain-Consumer-Genetics-Business-and-Advance-Shared-Goals-of-Improving-Human-Health-and-Wellness.pdf\">Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe\u00ae for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/Regeneron-Enters-into-Asset-Purchase-Agreement-to-Acquire-23andMe\u00ae-for-256-Million-Plans-to-Maintain-Consumer-Genetics-Business-and-Advance-Shared-Goals-of-Improving-Human-Health-and-Wellness.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c297dfb5-f743-4a6f-93fe-4f56b11f3507\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33794,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1166,1426],"class_list":["post-33792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nasdaq-regn","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regeneron Wins Auction for 23andMe&#039;s Core Business Units - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe&#039;s Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe&#039;s Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe&#039;s direct-to-consumer services post-acquisition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33792\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Wins Auction for 23andMe&#039;s Core Business Units\" \/>\n<meta property=\"og:description\" content=\"US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe&#039;s Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe&#039;s Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe&#039;s direct-to-consumer services post-acquisition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33792\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-21T00:44:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-21T00:44:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron Wins Auction for 23andMe&#8217;s Core Business Units\",\"datePublished\":\"2025-05-21T00:44:47+00:00\",\"dateModified\":\"2025-05-21T00:44:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2009.webp\",\"keywords\":[\"NASDAQ: REGN\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33792#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33792\",\"name\":\"Regeneron Wins Auction for 23andMe's Core Business Units - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2009.webp\",\"datePublished\":\"2025-05-21T00:44:47+00:00\",\"dateModified\":\"2025-05-21T00:44:48+00:00\",\"description\":\"US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe's Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe's Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe's direct-to-consumer services post-acquisition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33792\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2009.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2009.webp\",\"width\":1080,\"height\":608,\"caption\":\"Regeneron Wins Auction for 23andMe's Core Business Units\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33792#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Wins Auction for 23andMe&#8217;s Core Business Units\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron Wins Auction for 23andMe's Core Business Units - Insight, China&#039;s Pharmaceutical Industry","description":"US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe's Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe's Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe's direct-to-consumer services post-acquisition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33792","og_locale":"en_US","og_type":"article","og_title":"Regeneron Wins Auction for 23andMe's Core Business Units","og_description":"US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe's Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe's Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe's direct-to-consumer services post-acquisition.","og_url":"https:\/\/flcube.com\/?p=33792","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-21T00:44:47+00:00","article_modified_time":"2025-05-21T00:44:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33792#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33792"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron Wins Auction for 23andMe&#8217;s Core Business Units","datePublished":"2025-05-21T00:44:47+00:00","dateModified":"2025-05-21T00:44:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33792"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33792#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp","keywords":["NASDAQ: REGN","Regeneron Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33792#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33792","url":"https:\/\/flcube.com\/?p=33792","name":"Regeneron Wins Auction for 23andMe's Core Business Units - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33792#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33792#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp","datePublished":"2025-05-21T00:44:47+00:00","dateModified":"2025-05-21T00:44:48+00:00","description":"US-based biopharma Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced this week that it has successfully bid in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co. Regeneron will acquire 23andMe's Personal Genome Service (PGS), Total Health and Research Services business lines, along with its Biobank and associated assets, for USD 256 million. The transaction, which excludes 23andMe's Lemonaid Health business, is expected to close in the third quarter of this year. Regeneron plans to maintain uninterrupted operation of 23andMe's direct-to-consumer services post-acquisition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33792#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33792"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33792#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp","width":1080,"height":608,"caption":"Regeneron Wins Auction for 23andMe's Core Business Units"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33792#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Wins Auction for 23andMe&#8217;s Core Business Units"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2009.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33792"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33792\/revisions"}],"predecessor-version":[{"id":33795,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33792\/revisions\/33795"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33794"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}